Ectodomain Lysines and Suramin Block of P2X1 Receptors

被引:27
作者
Sim, Joan A. [1 ]
Broomhead, Helen E. [1 ]
North, R. Alan [1 ]
机构
[1] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England
基金
英国惠康基金;
关键词
D O I
10.1074/jbc.M802523200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
P2X(1) receptors belong to a family of cation channels gated by extracellular ATP; they are found inter alia in smooth muscle, platelets, and immune cells. Suramin has been widely used as an antagonist at P2X receptors, and its analog 4,4',4 '',4 '''-[carbonylbis((imino-5,1,3-benzenetriylbis(carbonylimino))] tetrakis-benzene-1,3- disulfonic acid (NF449) is selective for the P2X(1) subtype. Human and mouse P2X(1) receptors were expressed in human embryonic kidney cells, and membrane currents evoked by ATP were recorded. ATP (10 nM to 100 mu M) was applied only once to each cell, to avoid the profound desensitization exhibited by P2X(1) receptors. Suramin (10 mu M) and NF449 (3-300 nM)effectively blocked the human receptor. Suramin had little effect on the mouse receptor. Suramin and NF449 are polysulfonates, with six and eight negative charges, respectively. We hypothesized that species differences might result from differences in positive residues presented by the large receptor ectodomain. Four lysines in the human sequence (Lys(111), Lys(127), Lys(138), and Lys(148)) were changed individually and together to their counterparts in the mouse sequence. The substitution K138E, either alone or together with K111Q, K127Q, and K148N, reduced the sensitivity to block by both suramin and NF449. Conversely, when lysine was introduced into the mouse receptor, the sensitivity to block by suramin and NF449 was much increased for E138K, but not for Q111K, Q127K, or N148K. The results explain the marked species difference in antagonist sensitivity and identify an ectodomain lysine residue that plays a key role in the binding of both suramin and NF449 to P2X(1) receptors.
引用
收藏
页码:29841 / 29846
页数:6
相关论文
共 31 条
[1]   NF449:: a subnanomolar potency antagonist at recombinant rat P2X1 receptors [J].
Braun, K ;
Rettinger, J ;
Ganso, M ;
Kassack, M ;
Hildebrandt, C ;
Ullmann, H ;
Nickel, P ;
Schmalzing, G ;
Lambrecht, G .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 364 (03) :285-290
[2]   An antagonist-insensitive P-2X receptor expressed in epithelia and brain [J].
Buell, G ;
Lewis, C ;
Collo, G ;
North, RA ;
Surprenant, A .
EMBO JOURNAL, 1996, 15 (01) :55-62
[3]   IS THERE A BASIS FOR DISTINGUISHING 2 TYPES OF P2-PURINOCEPTOR [J].
BURNSTOCK, G ;
KENNEDY, C .
GENERAL PHARMACOLOGY, 1985, 16 (05) :433-440
[4]   SURAMIN - POTENT INHIBITOR OF THE REVERSE-TRANSCRIPTASE OF RNA TUMOR-VIRUSES [J].
DECLERCQ, E .
CANCER LETTERS, 1979, 8 (01) :9-22
[5]   SURAMIN - A REVERSIBLE P2-PURINOCEPTOR ANTAGONIST IN THE MOUSE VASDEFERENS [J].
DUNN, PM ;
BLAKELEY, AGH .
BRITISH JOURNAL OF PHARMACOLOGY, 1988, 93 (02) :243-245
[6]   The role of positively charged amino acids in ATP recognition by human P2X1 receptors [J].
Ennion, S ;
Hagan, S ;
Evans, RJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (38) :29361-29367
[7]  
EVANS RJ, 1995, MOL PHARM, V48, P17
[8]   Primary and secondary agonists can use P2X1 receptors as a major pathway to increase intracellular Ca2+ in the human platelet [J].
Fung, C. Y. E. ;
Cendana, C. ;
Farndale, R. W. ;
Mahaut-Smith, M. P. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (05) :910-917
[9]   NF449, a novel picomolar potency antagonist at human P2X1 receptors [J].
Hülsmann, M ;
Nickel, P ;
Kassack, M ;
Schmalzing, G ;
Lambrecht, G ;
Markwardt, F .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 470 (1-2) :1-7
[10]   Characterization of functional P2X1 receptors in mouse megakaryocytes [J].
Ikeda, Masahiro .
THROMBOSIS RESEARCH, 2007, 119 (03) :343-353